Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Receivables (2018 - 2025)

Dna X (SONM) has disclosed Receivables for 8 consecutive years, with $13.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 33.24% year-over-year to $13.3 million, compared with a TTM value of $13.3 million through Sep 2025, up 33.24%, and an annual FY2024 reading of $14.0 million, down 46.6% over the prior year.
  • Receivables was $13.3 million for Q3 2025 at Dna X, up from $12.5 million in the prior quarter.
  • Across five years, Receivables topped out at $33.6 million in Q3 2023 and bottomed at $5.8 million in Q1 2021.
  • Average Receivables over 5 years is $16.3 million, with a median of $13.4 million recorded in 2024.
  • The sharpest move saw Receivables surged 280.82% in 2023, then tumbled 70.21% in 2024.
  • Year by year, Receivables stood at $13.1 million in 2021, then skyrocketed by 90.04% to $24.8 million in 2022, then grew by 5.84% to $26.3 million in 2023, then crashed by 46.6% to $14.0 million in 2024, then dropped by 4.89% to $13.3 million in 2025.
  • Business Quant data shows Receivables for SONM at $13.3 million in Q3 2025, $12.5 million in Q2 2025, and $11.3 million in Q1 2025.